Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Green Cross Obtains South Korean Approval For Peramivir During Drive To Secure More Anti-Influenza Medicines Beyond Roche and GSK Products

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Green Cross has obtained approval from South Korea's FDA to sell the injectable antiviral drug Rapiacta (peramivir), developed by BioCryst Pharmaceuticals in the U.S., during a government drive to make more flu-fighting medicines available beyond Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir)

You may also be interested in...



Korea Provides Tamiflu Government Stockpile To Roche

To help cope with the rising number of patients with A/H1N1, Korea handed over some of its government stockpile of Tamiflu supplies to Roche.

Korea’s Celltrion Advances Its First Novel Therapy, Universal Influenza Treatment

Beyond its main focus of biosimilars, Celltrion is pursuing an influenza therapy that would be its first original product.

South Korea Won’t Extend Stockpiled Tamiflu Expiration Dates

MFDS rejects Korea Centers for Disease Control and Prevention bid to retain expiring Tamiflu stockpile. South Korea would need to replace expiring supplies to maintain same levels of stockpile.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC075727

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel